At Mankind Pharma, we believe sustainability goes beyond adopting green practices—it’s about rethinking how we produce, consume, and dispose of materials. By embracing the principles of the circular economy, we are making strides toward waste reduction, resource optimization, and minimizing environmental impact.

One of our most ambitious goals is achieving Plastic Neutrality by Financial Year 2024, a commitment that reflects our dedication to reducing our environmental footprint and aligning with the growing consumer demand for responsible waste management.

Achieving Plastic Neutrality

Our journey to Plastic Neutrality focuses on:

• Reducing plastic use in product packaging.
• Enhancing recycling efforts.
• Diverting waste from landfills.

These efforts have helped us neutralize the plastic footprint of our product packaging, ensuring that the waste generated by consumers is responsibly managed. In Financial Year 2024, we successfully:

• Collected 100% of post-consumer product packaging plastic.
• Recycled 8008 MT of rigid and flexible post-consumer plastic through third-party partnerships, preventing it from ending up in landfills.

This achievement demonstrates the power of innovation, accountability, and collaboration in tackling the challenges of plastic waste management.

Strategic Hazardous Waste Management

Managing hazardous and non-hazardous waste responsibly is critical to achieving our circular economy goals. By adopting a multi-pronged approach, we aim to ensure that by 2027, 70% of hazardous waste is disposed of through co-processing and 30% through landfilling, using Financial Year 2021 as the base year.

To meet this commitment, we have implemented several strategies:

• Extended partnerships with co-processors and recyclers to handle hazardous waste effectively.
• Invested in co-processing technology and waste segregation systems to optimize waste management.
• Developed waste categorization and monitoring frameworks for better accountability and transparency.

FY 2024 Milestones in Waste Management

Our focused efforts toward circularity resulted in significant milestones in Financial Year 2024:

• 28.6% increase in co-processing of waste compared to the previous year.
• 59.9% increase in waste recycling, showcasing our progress in transitioning to sustainable practices.

Key actions that drove these results include:

• 100% Collection and Recycling of Plastic: Ensuring that all post-consumer product packaging plastic is collected and recycled, eliminating waste from our value chain.
• Eliminating Virgin Plastic: Completely removing virgin plastic trays used in vial packaging, replacing them with sustainable alternatives.
• Advanced Waste Processing Technology:
  • Investing in sludge dewatering volute press and paddle dryer systems to reduce moisture content in effluent treatment plant (ETP) sludge, making it suitable for co-processing.
• Collaborations for Circularity:
  • Partnering with cement plants to recover energy from waste materials.
  • Disposing of boiler ash to brick manufacturing plants for recycling and reuse.

Moving Toward a Circular Future

At Mankind Pharma, circularity is not just a goal—it’s a mindset. By aligning our practices with circular economy principles, we continue to close the loop on waste management while fostering innovation and collaboration.

As we move forward, we remain committed to:

• Scaling up our waste diversion efforts.
• Exploring innovative technologies for resource recovery.
• Strengthening partnerships with recyclers, co-processors, and industry leaders.

Our progress is a testament to the tangible impact of embracing circular economy practices. Together, we can drive sustainability, inspire change, and create a healthier, waste-free planet.